Immune Pharmaceuticals, Inc. (NYSE:IMNP) closed its last session at $0.61. The stock traded within a range of $0.580 and $0.680. The company operates in the Healthcare sector with a market capitalization of 11100. Trading volume for Immune Pharmaceuticals, Inc. was 5.56 Million in its previous trading session. Currently, Immune Pharmaceuticals, Inc. (NYSE:IMNP) has an average volume of 805.77 Million.
Immune Pharmaceuticals Ltd. is a biopharmaceutical company which is engaged in the development of monoclonal antibodies for the treatment of inflammatory diseases and cancer. The company operates primarily in Israel and the United States. Immune Pharmaceuticals Inc., formerly known as EpiCept Corporation, is based in in Herzliya Pituach, Israel.
Immune Pharmaceuticals, Inc. (NYSE:IMNP) received a Buy rating from 1 analysts. 0 analysts gave its stock an Outperform rating. 0 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.
Immune Pharmaceuticals, Inc. (NYSE:IMNP) touched its 1-Year High price of $5.020 on 04/20/17 and its 1-Year Low price of $0.500 on 12/21/17.
EPS & Financials
Immune Pharmaceuticals, Inc. (NYSE:IMNP) reported its EPS in the last quarter as $-3.2/Share lagging the analyst estimate of $-2.7/Share by a difference of $-0.5. This showed a surprise of -18.5% in the last quarter earnings.
For the current quarter, 0 analysts are projecting a mean EPS of $0/share. According to their observations and findings, the stock could provide a high EPS of $0/share and a low EPS of $0/share.
By taking a look at the stock’s current statistics it can gauged that the stock candle is BEARISH with MEDIUM volatility. Immune Pharmaceuticals, Inc. (NYSE:IMNP) has a 20-Day average volume of 1.47 Million. According to today’s trading volume Immune Pharmaceuticals, Inc. is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.
The company currently has an insider ownership of 5.01 Percent and Institutional ownership of 2 Percent. The return on assets stands at -127.5%, Return on Equity currently is 0% and the Return on Investment value is 0%.
Immune Pharmaceuticals, Inc. (NYSE:IMNP) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving below its 20-Day Simple Moving Average of -1.8% with a 50-Day Simple Moving Average of -19.48 percent. As of today, the company has a SMA200 (200-day simple moving average) of -65.55 Percent. The Stock has YTD (year to date) performance of 7.39 percent.
The TTM operating margin for the company stands at 0%. The return on invested capital is at 0%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.
The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -65.55%, and has a solid year to date (YTD) performance of 7.39% which means that the stock is constantly adding to its value from the previous fiscal year end price.